When a PET-Positive Retroperitoneal Mass Is Not Prostate Cancer Metastasis: Imaging Diagnosis of Retroperitoneal Schwannoma
A Case Study in Medical Imaging of a Man in His 50s with Elevated PSA Levels
Executive Answer
A small retroperitoneal mass detected during evaluation of rising prostate-specific antigen (PSA) should not automatically be interpreted as metastatic prostate cancer. In this case, a 58-year-old man undergoing surveillance after prostate cancer treatment had a 1.6 × 1.3 cm left retroperitoneal soft-tissue lesion on CT with increased uptake on F-18 fluciclovine PET/CT. No other significant tracer-avid lesions were identified in the chest, abdomen, or pelvis. The final diagnosis was a primary retroperitoneal schwannoma. The key lesson is that tracer uptake is an imaging observation, not a histologic diagnosis. Location, morphology, distribution, interval growth, and clinical context must be integrated before labeling an isolated lesion as metastatic disease.
Why This Case Matters
One of the most important principles in oncologic imaging is deceptively simple:
A new lesion in a patient with cancer is not necessarily a metastasis.
The problem becomes particularly important when the new lesion appears during evaluation of a biochemical abnormality that already raises concern for recurrent disease.
In this case, PSA had increased during surveillance after treatment for prostate cancer. CT and F-18 fluciclovine PET/CT then demonstrated a small left retroperitoneal soft-tissue mass with increased tracer uptake.
That combination naturally creates a strong diagnostic expectation: prostate cancer recurrence with metastatic lymph-node involvement.
However, the final diagnosis was a primary retroperitoneal schwannoma.
This case therefore illustrates more than an uncommon tumor. It demonstrates a recurring radiology problem: how to interpret an imaging finding when the patient's established cancer diagnosis creates a powerful anchoring effect.
The practical lesson is not to ignore the possibility of metastasis. Rather, it is to determine whether the lesion actually behaves like the expected metastatic disease pattern.
Clinical Scenario
The patient was a 58-year-old man with a history of prostate cancer who had received multidisciplinary treatment and was undergoing active surveillance.
During the preceding six months, his PSA had increased significantly, prompting additional imaging evaluation.
Abdominal and pelvic CT and F-18 fluciclovine PET/CT were performed to evaluate for recurrent or metastatic disease.
CT demonstrated an approximately 1.6 × 1.3 cm soft-tissue lesion in the left retroperitoneum.
Because of the patient's prostate cancer history and rising PSA, metastatic lymph-node disease was an important consideration.
However, the imaging findings did not establish that diagnosis.
F-18 fluciclovine PET/CT demonstrated increased tracer uptake in the same retroperitoneal lesion. Importantly, no significant tracer-avid abnormalities were reported elsewhere in the chest, abdomen, or pelvis.
The final diagnosis was primary retroperitoneal schwannoma.
The Key Imaging Clue
The most important imaging clue was not simply that the lesion was PET-positive.
The more useful question was:
Does the entire imaging pattern convincingly support metastatic prostate cancer?
The lesion was:
Small, approximately 1.6 × 1.3 cm
Located in the left retroperitoneum
Associated with increased F-18 fluciclovine uptake
Described as an isolated lesion
Not accompanied by significant tracer-avid disease elsewhere in the chest, abdomen, or pelvis
This pattern requires a differential diagnosis rather than an automatic metastatic diagnosis.
The distinction is fundamental:
Increased tracer uptake is an imaging finding.
Metastatic prostate cancer is a biologic and histopathologic diagnosis.
Those two statements should not be treated as interchangeable.
Figure 1 — Coronal CT
Radiologic Interpretation
The coronal CT image demonstrates an approximately 1.6 × 1.3 cm soft-tissue lesion in the left retroperitoneum.
The lesion is located in a region where metastatic lymph-node disease must be considered in a patient with prostate cancer. At the same time, its location does not by itself establish nodal origin.
The radiologist should evaluate:
The exact retroperitoneal location
Relationship to the aorta and inferior vena cava
Relationship to the kidneys, ureters, psoas muscles, and adjacent structures
Whether the lesion is solitary or part of a nodal distribution
Whether a prior examination demonstrates stability or growth
Clinical Significance
Coronal imaging is particularly useful for understanding the superior-inferior position of a small retroperitoneal lesion and its relationship to adjacent structures.
For a small mass, anatomic localization can provide the first clue that the lesion may not represent a conventional lymph node.
However, a single image cannot reliably establish the precise nerve of origin or definitively classify the tumor.
Figure 2 — Axial Contrast-Enhanced CT
Radiologic Interpretation
The axial contrast-enhanced CT image demonstrates the left retroperitoneal soft-tissue lesion, measuring approximately 1.6 × 1.3 cm.
The major diagnostic problem is distinguishing a possible metastatic lymph node from a primary retroperitoneal soft-tissue or nerve-related tumor.
The following features deserve careful assessment:
Does the lesion follow a recognizable lymph-node distribution?
Is there an association with the expected course of a nerve?
Is the margin well-defined or infiltrative?
What is the enhancement pattern?
Is there internal necrosis, cystic change, or hemorrhage?
Does the lesion displace, encase, or invade adjacent vessels?
A relatively well-defined lesion should not automatically be considered benign, and an unusual enhancement pattern should not independently establish schwannoma.
Figure 3 — Axial F-18 Fluciclovine PET/CT
Radiologic Interpretation
The axial PET/CT image demonstrates increased F-18 fluciclovine uptake in the left retroperitoneal soft-tissue lesion.
No significant tracer-avid lesions were reported elsewhere in the chest, abdomen, or pelvis.
The important interpretive step is to correlate the PET finding directly with the CT morphology.
The question is not simply:
“Is the lesion fluciclovine-avid?”
The more clinically useful question is:
“Does the location, morphology, distribution, and tracer behavior collectively support metastatic prostate cancer?”
In this case, the answer was ultimately no.
Why F-18 Fluciclovine Uptake Does Not Equal Prostate Cancer Metastasis
F-18 fluciclovine is an amino-acid analog used in the evaluation of biochemical recurrence of prostate cancer.
However, it is not exclusively taken up by prostate cancer.
Some nonprostatic neoplasms can demonstrate increased fluciclovine uptake because of tumor biology and expression of relevant amino-acid transport mechanisms.
This creates an important radiology distinction:
Imaging fact
The retroperitoneal lesion demonstrates increased F-18 fluciclovine uptake.
Diagnostic conclusion
The lesion is metastatic prostate cancer.
The first statement is supported by imaging.
The second requires a broader clinical-radiologic assessment and, when necessary, pathologic confirmation.
This distinction is particularly important when the lesion is isolated or atypical for the expected metastatic distribution.
Published literature has specifically described extraprostatic F-18 fluciclovine uptake and the potential difficulty of distinguishing nonprostatic neoplasms from metastatic prostate cancer.
Radiologist's Reasoning: From “Metastasis?” to “What Else Could This Be?”
A useful approach to a small retroperitoneal mass in a patient with cancer is to move through several questions.
Question 1: Where exactly is the lesion?
Anatomic localization is the foundation of the differential diagnosis.
Determine whether the lesion is:
Para-aortic
Pericaval
Perirenal
Paravertebral
Adjacent to the psoas
Along a possible nerve pathway
Within a typical lymph-node station
The exact location can substantially change the differential diagnosis.
Question 2: Is it actually behaving like a lymph node?
A solitary small retroperitoneal lesion may resemble a lymph node.
But a radiologist should assess whether the lesion follows the expected distribution of metastatic nodes and whether additional nodes or distant lesions are present.
A solitary lesion with an unusual location or morphology deserves more scrutiny.
Question 3: Is there evidence of disease elsewhere?
Distribution is one of the most useful contextual clues in oncologic imaging.
If widespread metastatic disease is present, an isolated retroperitoneal lesion may fit naturally into that pattern.
If the lesion is isolated, however, the diagnostic threshold for automatically labeling it metastatic should be higher.
This does not exclude metastasis.
It simply preserves diagnostic uncertainty until the evidence is sufficient.
Question 4: Could this be a nerve-sheath tumor?
Schwannomas arise from Schwann cells associated with peripheral nerves.
Retroperitoneal schwannomas are uncommon but biologically plausible because the retroperitoneum contains autonomic and peripheral nerve structures.
MRI may be particularly helpful when a nerve-related origin is suspected.
Potential imaging clues include:
Relationship to a nerve
High T2 signal
Internal heterogeneity related to degeneration
Split-fat sign
Target sign
Fascicular sign
These findings can support the possibility of a nerve-sheath tumor, but none should be regarded as pathognomonic for schwannoma.
Differential Diagnosis of a Small Retroperitoneal Soft-Tissue Mass
The differential diagnosis should remain broad enough to accommodate both the patient's cancer history and the lesion's imaging characteristics.
| Diagnosis | Key consideration |
|---|---|
| Metastatic lymph node | Prostate cancer history, PSA elevation, nodal distribution, additional metastatic disease |
| Schwannoma | Nerve-related location, morphology, MRI characteristics |
| Liposarcoma | Macroscopic fat and non-fatty solid components |
| Leiomyosarcoma | Large soft-tissue mass, necrosis, vascular relationship |
| Lymphoma | Nodal distribution and additional lymphadenopathy |
| Ganglioneuroma | Nerve/ganglion-related location and internal architecture |
| Retroperitoneal fibrosis | Periaortic soft tissue and ureteral involvement |
| Retroperitoneal teratoma | Combination of fat, fluid, and calcification |
| Abscess | Infection, inflammatory change, and clinical context |
This differential is not a checklist for diagnosing every lesion from CT alone. Instead, it provides a framework for deciding which diagnostic pathway is appropriate.
Schwannoma Versus Metastatic Lymph Node
This is the central diagnostic problem in the case.
Features favoring metastatic disease
Typical nodal distribution
Multiple enlarged or abnormal nodes
Other metastatic lesions
Imaging progression consistent with known prostate cancer
Clinical and biochemical evidence supporting recurrence
Features that should prompt consideration of schwannoma or another primary retroperitoneal tumor
Solitary lesion
Unusual nodal location
Relationship to a nerve
Imaging characteristics suggestive of a nerve-sheath tumor
Absence of other convincing metastatic disease
Atypical overall distribution
The presence of one or more of these features does not prove schwannoma.
Rather, they should prevent premature closure.
MRI: When It Adds Diagnostic Value
MRI can be useful when CT cannot confidently establish the origin or tissue characteristics of a retroperitoneal mass.
Its major advantage is superior soft-tissue contrast.
A typical schwannoma may demonstrate relatively low or intermediate T1 signal and high T2 signal, although signal characteristics vary according to cellularity, myxoid change, cystic degeneration, and hemorrhage.
Contrast-enhanced MRI can help distinguish enhancing solid components from degenerative regions.
Fat-suppressed sequences can also assist in evaluating fat-containing lesions.
The purpose of MRI is therefore not simply to “confirm schwannoma.”
Its more important role is to answer practical questions:
Is a nerve-related origin plausible?
Is there an aggressive infiltrative component?
What is the internal composition?
What is the relationship to nearby nerves and vessels?
Would additional imaging alter the management decision?
When Should Biopsy Be Considered?
Imaging cannot always distinguish metastatic disease from a primary retroperitoneal tumor with sufficient confidence.
Image-guided core biopsy may be considered when:
Imaging remains indeterminate
Malignancy is a meaningful concern
The result could change treatment
The lesion is technically accessible
The expected diagnostic benefit outweighs procedural risk
Biopsy should not be treated as an automatic requirement for every retroperitoneal mass.
The decision should incorporate lesion location, vascular relationships, potential access routes, bleeding risk, and the likelihood that pathology will change management.
Pathologic Considerations
Schwannoma is a peripheral nerve-sheath tumor.
Histologic assessment may demonstrate spindle-cell morphology and characteristic architectural patterns.
Immunohistochemical markers such as S-100 protein and SOX10 can support the diagnosis when interpreted together with morphology.
No single immunohistochemical marker should be used in isolation to establish the diagnosis.
This is another important reason why imaging and pathology should be viewed as complementary rather than competing diagnostic systems.
Why This Finding Can Be Missed
This case illustrates several potential diagnostic vulnerabilities.
Anchoring
Once a patient has a known malignancy and rising PSA, a new lesion may be mentally assigned to the established cancer diagnosis before its imaging characteristics are fully analyzed.
Satisfaction of Search
The primary purpose of PET/CT may be to identify recurrent prostate cancer. Once an apparently suspicious lesion is found, attention may shift away from questioning whether the lesion itself is correctly characterized.
Non-target Abnormality
The lesion is relevant to the examination but is not necessarily the disease process the examination was originally intended to evaluate.
Pattern Completion
A radiologist may unconsciously complete a familiar clinical pattern:
prostate cancer + rising PSA + retroperitoneal lesion + tracer uptake = metastasis
The problem is that each individual component may be true while the final conclusion remains incorrect.
The appropriate response is not to distrust pattern recognition. Pattern recognition is essential in radiology.
The safeguard is to deliberately test the pattern against discordant evidence.
Diagnostic Risk Perspective
The clinical risk in this type of case is not limited to missing a schwannoma.
A premature metastatic diagnosis can potentially change the patient's cancer staging and treatment pathway.
That may lead to:
Additional imaging
Additional procedures
Alteration of oncologic management
Unnecessary treatment escalation
Increased patient anxiety
Additional healthcare resource utilization
Conversely, assuming that every isolated lesion is benign could delay diagnosis of true metastatic disease.
Therefore, the correct principle is not:
“Do not call it metastasis.”
It is:
“Do not call it metastasis without integrating the entire imaging and clinical pattern.”
When Observation May Be Reasonable
Some retroperitoneal schwannomas are discovered incidentally and may be managed with imaging surveillance when they are asymptomatic and imaging suggests a low likelihood of aggressive behavior.
A natural-history study cited in the source case followed 22 patients under observation, with a mean follow-up of approximately 48 months and a reported mean growth rate of 1.9 mm per year. Most patients remained without surgery during observation, while two underwent surgery because of tumor enlargement.
These findings support the possibility of observation in selected patients, but they should not be interpreted as a universal growth rule.
Follow-up should be individualized according to:
Tumor size
Morphology
Symptoms
Interval change
Anatomic relationships
Clinical risk
When Surgery May Be Considered
Surgical resection may be considered when there are:
Persistent or progressive symptoms
Increasing tumor size
Compression of adjacent organs or nerves
Imaging features concerning for malignancy
Persistent diagnostic uncertainty in a situation where resection provides appropriate diagnostic or therapeutic value
The retroperitoneum contains major vessels, ureters, and important neural structures.
Therefore, surgical planning must consider not only tumor removal but also preservation of surrounding anatomy and function.
AI Perspective: Could Medical AI Help With This Case?
This case is relevant to medical AI, but the role of AI should be defined realistically.
A potential application is second-reader support rather than autonomous diagnosis.
An imaging AI system could potentially assist with:
Detection of small soft-tissue abnormalities
Lesion localization
Measurement
Comparison with prior examinations
Structured follow-up
Prioritization of potentially significant findings
However, detecting a small retroperitoneal lesion is not the same as determining whether it is metastatic prostate cancer or schwannoma.
That distinction remains clinically difficult because the diagnosis depends on anatomy, morphology, disease distribution, clinical history, and sometimes pathology.
AI Failure Modes in This Case
An AI system could fail in several ways.
False Negative
A small retroperitoneal lesion may be overlooked because of size, image quality, anatomical complexity, or model limitations.
False Positive
The system may flag an anatomically normal structure or benign lesion as suspicious.
Anatomical Mislocalization
A model may detect an abnormality but incorrectly classify its anatomic compartment or nodal station.
Unexpected Pathology
A system trained primarily on common metastatic disease may perform less reliably when confronted with an uncommon benign tumor such as retroperitoneal schwannoma.
Automation Bias
The greatest clinical danger may occur when a radiologist accepts an AI output without independently verifying the finding.
The fundamental principle is:
AI does not eliminate diagnostic responsibility. AI may redistribute attention.
AI Workflow Implication
A realistic enterprise workflow might look like:
DICOM à PACS à AI Orchestration à AI Detection / Quantification à PACS Visualization à Radiologist Review à RIS à EHR/EMR à Clinical Decision Support
The most useful AI application in this scenario would be one that helps the radiologist notice and characterize an abnormality without forcing a premature diagnosis.
An AI system should ideally support the question:
“What abnormality is present, and what should I evaluate next?”
rather than simply:
“Is this metastatic prostate cancer?”
The second question is substantially harder and requires broader clinical reasoning.
Healthcare Workflow and System Value
This case demonstrates why incidental and non-target findings are important in high-volume imaging workflows.
The original clinical concern may be recurrent prostate cancer. Yet the imaging examination can reveal a different clinically meaningful process.
This creates a workflow challenge:
Targeted examination → unexpected abnormality → diagnostic reclassification
Radiology systems that prioritize only the primary clinical question may risk under-recognizing unexpected findings.
The opportunity for AI is therefore not necessarily to replace interpretation but to support:
Detection
Prior comparison
Measurement consistency
Worklist prioritization
Structured communication
Follow-up tracking
Any claimed benefit would depend on model performance, workflow integration, false-positive burden, human adoption, and appropriate clinical oversight.
No specific AI performance or cost savings should be assumed without independent evidence.
Healthcare Economics: Why Diagnostic Precision Matters
A mistaken metastatic interpretation can have system-level consequences even when no specific financial value is available.
Potential downstream effects include:
Additional imaging
Additional consultations
Biopsy procedures
Treatment changes
Repeat examinations
Increased clinical workload
Longer diagnostic pathways
At the same time, excessive testing of every indeterminate lesion also consumes resources.
The economically rational approach is therefore not simply “more testing.”
It is testing that has a reasonable probability of changing management or reducing meaningful diagnostic uncertainty.
Common Pitfalls
Pitfall 1: “The patient has prostate cancer, so the mass is metastatic.”
Cancer history changes the prior probability. It does not establish the diagnosis.
Pitfall 2: “The lesion is fluciclovine-avid, so it must be prostate cancer.”
Tracer uptake is not equivalent to histologic identity.
Pitfall 3: “It is a solitary lesion, so it cannot be metastatic.”
Solitary metastasis remains possible. Distribution is supportive evidence, not an exclusion rule.
Pitfall 4: “A smooth margin means benign.”
Morphologic appearance should be interpreted in context.
Pitfall 5: “MRI proves schwannoma.”
MRI may strengthen the nerve-sheath tumor differential, but imaging alone may not provide definitive histology.
Pitfall 6: “Every indeterminate lesion needs immediate surgery.”
Management should balance diagnostic uncertainty, symptoms, growth, malignancy risk, anatomy, and procedural risk.
Practical Radiology Pearls
Pearl 1: A new lesion in a cancer patient deserves an oncologic differential diagnosis, not an automatic metastatic label.
Pearl 2: Always separate tracer uptake from histologic diagnosis.
Pearl 3: For small retroperitoneal lesions, precise anatomic localization is essential.
Pearl 4: Solitary disease should prompt careful review of distribution and prior imaging.
Pearl 5: MRI can be useful when a nerve-sheath tumor is part of the differential.
Pearl 6: Rapid growth, infiltrative margins, extensive necrosis, organ or vascular invasion, new multifocal disease, and progressive neurologic or urinary symptoms increase concern and may justify additional evaluation.
Pearl 7: The best next test is the one most likely to change the clinical decision.
Pearl 8: AI can help detect and prioritize abnormalities, but it cannot independently resolve every clinical differential.
Featured Imaging Questions
What is the key imaging finding?
The key finding is a small, approximately 1.6 × 1.3 cm left retroperitoneal soft-tissue lesion demonstrating increased F-18 fluciclovine uptake in a patient with rising PSA. The critical interpretive point is that the lesion was ultimately a primary retroperitoneal schwannoma rather than metastatic prostate cancer.
What is the most important differential diagnosis?
The principal differential is metastatic prostate cancer involving a retroperitoneal lymph node versus a primary retroperitoneal tumor such as schwannoma. Lymphoma, other soft-tissue sarcomas, ganglion-related tumors, retroperitoneal fibrosis, and infectious lesions may also be considered according to morphology and clinical context.
When is MRI useful?
MRI is useful when CT cannot confidently establish the origin or internal composition of a retroperitoneal mass. It can provide superior soft-tissue contrast and may reveal features supporting a nerve-sheath origin, while also evaluating relationships to adjacent structures.
When should biopsy be considered?
Biopsy can be considered when imaging remains indeterminate and the pathologic result is likely to change treatment or management. The decision should account for lesion location, vascular anatomy, access route, procedural risk, and the expected clinical value of tissue diagnosis.
FAQ
1. Can a schwannoma show F-18 fluciclovine uptake?
Yes. The case illustrates that increased F-18 fluciclovine uptake is not exclusively associated with prostate cancer. Nonprostatic neoplasms can demonstrate uptake, so tracer avidity should be interpreted with CT morphology, distribution, and clinical context.
2. Can a retroperitoneal schwannoma mimic a metastatic lymph node?
Yes. A small retroperitoneal schwannoma may appear as a soft-tissue mass in a location where metastatic nodal disease is also considered.
3. Does rising PSA prove that a retroperitoneal lesion is metastatic prostate cancer?
No. Rising PSA increases concern for recurrent disease but does not independently establish that a particular lesion is metastatic.
4. What CT findings should be assessed in a retroperitoneal mass?
Location, size, interval growth, margins, enhancement, internal composition, vascular relationships, adjacent-organ involvement, and the presence or absence of additional lesions should be evaluated.
5. What MRI findings may suggest a nerve-sheath tumor?
Potential clues include high T2 signal and signs such as split-fat, target, or fascicular patterns. These findings are supportive rather than definitive.
6. Is every retroperitoneal schwannoma treated surgically?
No. Selected asymptomatic lesions with low concern for aggressive behavior may be followed with imaging, whereas symptomatic, enlarging, anatomically problematic, or suspicious lesions may require intervention.
7. Can AI diagnose retroperitoneal schwannoma?
AI may assist with lesion detection, localization, measurement, comparison, and workflow prioritization, but an AI output should not be treated as a definitive histologic diagnosis.
8. What is the biggest diagnostic lesson from this case?
The most important lesson is to avoid anchoring on the patient's known malignancy. The radiologist should determine whether the new lesion actually fits the expected metastatic pattern before assigning a definitive diagnosis.
Key Takeaways
A rising PSA appropriately raises concern for recurrent or metastatic prostate cancer.
But the discovery of a new retroperitoneal lesion does not automatically establish metastatic disease.
In this case, the lesion demonstrated increased F-18 fluciclovine uptake but was ultimately diagnosed as a primary retroperitoneal schwannoma.
The diagnostic process therefore depends on integration of:
Clinical history
PSA trajectory
Precise lesion localization
CT morphology
PET/CT distribution
Prior imaging
MRI when appropriate
Pathology when necessary
Treatment implications
The broader lesson is applicable well beyond prostate cancer:
When an imaging finding does not completely fit the expected disease pattern, the correct response is not to force the finding into the existing diagnosis. The correct response is to reconsider the differential.
References
Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO classification of soft tissue tumours: News and perspectives. Pathologica. 2021;113(2):70–84. doi:10.32074/1591-951X-213.
Belakhoua SM, Rodriguez FJ. Diagnostic pathology of tumors of peripheral nerve. Neurosurgery. 2021;88(3):443–456. doi:10.1093/neuros/nyab021.
Schindler OS, Dixon JH, Case P. Retroperitoneal giant schwannomas: Report on two cases and review of the literature. Journal of Orthopaedic Surgery. 2002;10(1):77–84. doi:10.1177/230949900201000114.
Ogose A, et al. The natural history of incidental retroperitoneal schwannomas. PLOS ONE. 2019;14(4). doi:10.1371/journal.pone.0215336.
Robertson MS, Sakellis CG, Hyun H, Jacene HA. Extraprostatic uptake of 18F-fluciclovine: Differentiation of nonprostatic neoplasms from metastatic prostate cancer. American Journal of Roentgenology. 2020;214(3):641–648. doi:10.2214/AJR.19.21894.
Mota MMDS, Bezerra ROF, Garcia MRT. Practical approach to primary retroperitoneal masses in adults. Radiologia Brasileira. 2018;51(6):391–400. doi:10.1590/0100-3984.2017.0179.
Tomita K, et al. Computed tomography fluoroscopy-guided core needle biopsy of abdominal para-aortic lesions: A retrospective evaluation of the diagnostic yield and safety. Interventional Radiology. 2020;5(3):128–133. doi:10.22575/interventionalradiology.2020-0009.
Kallen ME, Hornick JL. The 2020 WHO Classification: What's new in soft tissue tumor pathology? Advances in Anatomic Pathology. 2021;28(1)–e23. doi:10.1097/PAS.0000000000001552.
Continue Learning
1. Prostate Cancer Imaging After Rising PSA
[INTERNAL LINK PLACEHOLDER]
2. CT and MRI Differential Diagnosis of Retroperitoneal Masses
[INTERNAL LINK PLACEHOLDER]
3. Imaging of Peripheral Nerve Sheath Tumors
[INTERNAL LINK PLACEHOLDER]
4. PET/CT Tracer Uptake and Non-Specific Tumor Findings
[INTERNAL LINK PLACEHOLDER]
5. CT-Guided Biopsy of Retroperitoneal Lesions
[INTERNAL LINK PLACEHOLDER]
Medical Disclaimer
This article is intended for medical education and informational purposes. It does not replace professional medical diagnosis or treatment. Individual patients should be evaluated by qualified healthcare professionals in the appropriate clinical context.
Comments
Post a Comment